New Drug, Generic, and Biosimilar Pipeline Report
By constantly monitoring the pipeline, you can ensure that you are providing the most clinically effective and cost-efficient options available. Here is what you can expect from our report:
- A list of newly approved brand-name drugs
- Key generic and biosimilar entries
- Administration routes, approval timelines, and cost projections
- Applicable therapeutic areas
We publish this pipeline report quarterly to assist your PBM planning and strategies. If you want to learn more, you can read about our clinical services and strategies or talk to a Sales Rep.
Click here to view or download the Q1 2024 pipeline report as a PDF.
New Drug Pipeline
| GENERIC NAME | BRAND NAME (Manufacturer if drug name unavailable) | ROUTE OF ADMINISTRATION | STATUS | ESTIMATED COST | THERAPEUTIC AREA | SPECIALTY OR TRADITIONAL |
| Bimekizumab** | Bimzelx | Subcutaneous | Launched Oct 2023 | $93,600 annually | Dermatology: Plaque Psoriasis | Specialty |
| Etrasimod** | Velsipity | Oral | Launched Oct 2023 | $75,000 annually | Gastrointestinal: Ulcerative Colitis | Specialty |
| Treprostinil DPI | Yutrepia | Inhaled* | Jan 2024 | TBD | Pulmonary Arterial Hypertension | Specialty |
| Scopolamine | (Repurposed Therapeutics/Defender Pharmaceuticals) | Nasal* | Jan 2024 | TBD | Gastrointestinal: Motion Sickness | Traditional |
| Atropine Sulfate | (Nevakar/Vyluma) | Ophthalmic* | Jan 2024 | $5,000 annually | Ophthalmic: Myopia | Traditional |
| Roluperidone | (Mitsubishi Tanabe Minerva) | Oral | Feb 2024 | $20,000-$30,000 annually | Central Nervous System: Schizophrenia | Traditional |
| Glatiramer Acetate | GA Depot | Intramuscular* | Mar 2024 | TBD | Central Nervous System: Multiple Sclerosis | Specialty |
| Givinostat | Duvyzat | Oral | Mar 2024 | $350,000 annually | Central Nervous System: Duchenne Muscular Dystrophy | Specialty |
| Sotatercept | (Merck) | Subcutaneous | Mar 2024 | $300,000-$500,000 annually | Pulmonary: Pulmonary Arterial Hypertension | Specialty |
| Aprocitentan | (Janssen) | Oral | Mar 2024 | TBD | Cardiovascular: Hypertension | Specialty |
| Resmetirom | (Madrigal) | Oral | Mar 2024 | $20,000-$50,000 annually | Endocrine: Metabolic Dysfunction associated Steatohepatitis (MASH) | Specialty |
| Vadadustat | Vafseo | Oral | Mar 2024 | TBD | Hematological Agents: Chronic Kidney Disease | Specialty |
| Leqembi (self-administered) | (Biogen/Eisai) | Subcutaneous* | 1Q2024 | $26,000 annually | Central Nervous System: Alzheimer’s Disease | Specialty |
| Bulevirtide | Mycludex or Hepcludex | Subcutaneous | 1Q2024 | TBD | Anti-Infectives: Antivirals | Specialty |
| Macitentan; Tadalafil STCT | (Janssen) | Oral | 1Q2024 | TBD | Pulmonary Arterial Hypertension | Specialty |
| Pivmecillinam | (LEO Pharma) | Oral | Apr 2024 | TBD | Anti-Infectives: Antibiotics | Traditional |
| Mavorixafor | (X4 Pharmaeuticals) | Oral | Apr 2024 | $100,000-$200,000 annually | Autoimmune | Specialty |
| Diazepam | Libervant | Oral* | Apr 2024 | TBD | Central Nervous System: Epilepsy | Specialty |
| Tovorafenib | (Day One Biopharmaceuticals/ Takeda) | Oral | Apr 2024 | $250,000 annually | Cancer: Brain | Specialty |
| Palopegteriparatide | TransCon PTH | Subcutaneous | May 2024 | $100,000-$300,000 annually | Endocrine: Hypoparathyroidism | Specialty |
| Rivoceranib | (Jiangsu Hengrui Medicine LSK BioPharma) | Oral | May 2024 | TBD | Cancer: Gastrointestinal | Specialty |
| Elafibranor | (Genfit; Ipsen) | Oral | Jun 2024 | TBD | Endocrine: Metabolic Dysfunction associated Steatohepatitis (MASH) | Specialty |
| Arimoclomol | Miplyffa | Oral | Jun 2024 | TBD | Endocrine: Niemann-Pick disease Type C | Specialty |
| Ensifentrine | (Verona Pharma) | Inhaled | Jun 2024 | $18,000 annually | Respiratory: Asthma/COPD | Traditional |
| Sofdra | (Sofpironium Bromide) | Topical | Jun 2024 | TBD | Dermatology: Hyperhidrosis | Traditional |
| Budesonide | Eohilia | Oral* | 1H2024 | TBD | Gastrointestinal: Eosinophilic Esophagitis | Specialty |
| Danicopan | (Alexion/ AstraZeneca) | Oral | 1H2024 | $100,000-$200,000 annually | Hematologic: Paroxysmal nocturnal hemoglobinuria | Specialty |
| Follitropin Delta | Rekovelle | Subcutaneous* | 1H2024 | TBD | Endocrine: Infertility | Specialty |
| Naloxone | Orexo | Nasal* | Jul 2024 | TBD | Addiction/Substance Abuse | Traditional |
| Crovalimab | (Roche/Chugai) | Intravenous/ Subcutaneous | Jul 2024 | $300,000-$500,000 | Hematological: Paroxysmal Nocturnal Hemoglobulinuria | Specialty |
| Galantamine Benzoate | (Alpha Cognition) | Oral | Jul 2024 | TBD | Central Nervous System: Alzheimer’s/Dementia | Traditional |
| Deuruxolitinib | (Concert/Sun) | Oral | Jul 2024 | TBD | Dermatology: Alopecia Areata | Specialty |
| Vonoprazan | Voquezna (Phathom Pharmaceuticals) | Oral | Jul 2024 | $8,000 annually | Gastrointestinal: Non-erosive reflux disease (NERD) | Traditional |
| Insulin icodec | (Novo Nordisk) | Subcutaneous | 2Q2024 | $5,000 annually | Endocrine:Diabetes | Traditional |
| Tradipitant | (Vanda Pharmaceuticals) | Oral | Sept 2024 | $10,000-$20,000 per course | Gastroenterology: Nausea | Specialty |
| Xanomeline; Trospium Chloride | KarXT | Oral | Sept 2024 | $20,000-$30,000 annually | Central Nervous System: Schizophrenia | Traditional |
| Lebrikizumab | (Eli Lilly) | Subcutaneous | 2H2024 | $50,000 | Dermatology: Atopic Dermatitis | Specialty |
| Seladelpar | (CymaBay Therapeutics) | Oral | 2H2024 | $110,000 annually | Gastrointestinal: Primary biliary cholangitis | Specialty |
| Midomafetamine (MDMA) | (MAPS PBC; Lykos Therapeutics) | Oral | 2H2024 | $5,000-$10,000 per course | Central Nervous System: Mood Disorders | Specialty |
| Govorestat | (Applied Therapeutics) | Oral | 2H2024 | TBD | Endocrine: Metabolic | Specialty |
| Revumenib | (Syndax) | Oral | 2H2024 | TBD | Cancer: Leukemia | Specialty |
| Glepaglutide | (Zeland Pharma) | Subcutaneous | 4Q2024 | $540,000 annually | Gastrointestinal: Short Bowel Syndrome | Specialty |
| Lazertinib | YuHan | Oral | 4Q2024 | TBD | Cancer: Non-Small Cell Lung Cancer | Specialty |
| Vicagrel | (Jiangsu Vcare Pharmatech) | Oral | 4Q2024 | TBD | Cardiovascular: Acute Cornoary Syndrome | Specialty |
| Acoramidis | (BridgeBio/Eidos Therapeutics) | Oral | 4Q2024 | $200,000 -$300,000 annually | Endocrine: Metabolic | Specialty |
| Reproxalap | (Aldeyra Therapeutics) | Topical: Ophthalmic | 4Q2024 | TBD | Ophthalmology: Dry Eye Disease | Traditional |
*New Formulation of an Existing Product
**Products appearing in green launched previously
Source: IPD Analytics 2024
Generic and Biosimilar Pipeline
| DRUG NAME | BRAND NAME | ROUTE OF ADMINISTRATION | STATUS | ESTIMATED 2022 US SALES (MILLIONS) | THERAPEUTIC AREA | BIOSIMILAR OR TRADITIONAL |
| Pitavastatin | Livalo | Oral | Launched Nov 2023 | $345 | Cardiology | Traditional |
| Gabapentin | Gralise | Oral | Jan 2024 | $100 | Central Nervous System | Traditional |
| Nilotinib | Tasigna | Oral | Jan 2024 | $2,200 | Cancer: Leukemia | Biosimilar |
| Deflazacort | Emflaza | Oral | Feb 2024 | $300 | Musculoskeletal: Duchenne Muscular Dystrophy | Biosimilar |
| Zymfentra (Infliximab) | Remicade* | Subcutaneous | Feb 2024 | $6,137 | Anti-Inflammatory | Biosimilar |
| Lamivudine/Raltegravir | Dutrebis | Oral | Mar 2024 | N/A | Anti-Infectives: HIV | Traditional |
| Risperidone | Risvan | Intramuscular | Mar 2024 | $15,000-$35,000/year | Central Nervous System: Antipsychotic | Traditional |
| Insulin Glargine | Lantus | Subcutaneous | 1Q2024 | $11,755 | Endocrine: Diabetes | Traditional |
| Zercepac (Trastuzumab) | Herceptin | Intravenous | 1Q2024 | $752 | Cancer: Breast | Biosimilar |
| Rapilin (Insulin Aspart) | Novolog | Subcutanous | Apr 2024 | $6,532 | Endocrine: Diabetes | Traditional |
| Prandilin (Insulin Lispro) | Humalog | Subcutaneous | Apr 2024 | $5,520 | Endocrine: Diabetes | Traditional |
| Xlucane (Ranibizumab) | Lucentis | Intravitreal* | Apr 2024 | $1,920 | Ophthalmic: Macular Degeneration | Biosimilar |
| Edaravone | Radicava | Intravenous | May 2024 | $330 | Central Nervous System: ALS | Biosimilar |
| Aflibercept | Eylea | Intravitreal | Jun 2024 | $6,795 | Ophthalmic: Macular Degeneration | Biosimilar |
| Liraglutide | Victoza | Subcutaneous | Jun 2024 | $3,700 | Endocrine: Diabetes | Traditional |
| Rituximab | Rituxan | Intravenous* | 2Q2024 | $2,035 | Anti-Inflammatory | Biosimilar |
| Tyruko (Natalizumab) | Tysabri | Intravenous* | 1H2024 | $1,783 | Central Nervous System: Multiple Sclerosis | Biosimilar |
| Ryzneuta (Efbemalenograstim Alfa-vuxw) | Neulasta | Subcutaneous* | 1H2024 | $1,006 | Cancer | Biosimilar |
| Filgrastim | Neupogen | Intravenous/Subcutaneous* | 1H2024 | $167 | Hematological Agents | Biosimilar |
| Dasatinib | Sprycel | Oral | Sept 2024 | $2,000 | Cancer | Biosimilar |
| Oxcarbazepine | Oxtellar XR | Oral | Sept 2024 | $230 | Central Nervous System: Epilepsy | Traditional |
| Teduglutide | Gattex | Subcutaneous | 2024 | $180 | Gastrointestinal | Biosimilar |
| Raltegravir | Isentress | Oral | 2024 | $320 | Anti-Infectives: HIV | Traditional |
| Denosumab | Prolia | Subcutaneous | 2024-2025 | $3,218 | Cancer | Biosimilar |
| Toclizumab (Tyenne) | Actemra | Intravenous* | 2024-2025 | $864 | Anti-Inflammator | Biosimilar |
| Ustekinumab | Stelara | Subcutaneous | Jan 2025 | $18,086 | Anti-Inflammatory | Biosimilar |
| Formoterol/Mometasone | Dulera | Inhaled | TBD | $500 | Respiratory | Traditional |
*New Formulation of an Existing Product
Source: IPD Analytics 2024
Nothing herein is or shall be construed as a promise or representation regarding past or future events and Serve You Rx expressly disclaims any and all liability relating to the use or reliance on the information contained in this publication. The information contained in this publication is intended for educational purposes only and should not be considered clinical, financial, or legal advice. By receipt of this publication, each recipient agrees that the information contained herein will be kept confidential and that the information will not be photocopied, reproduced, distributed to, or disclosed to others at any time without the prior written consent of Serve You Rx.
About Serve You Rx
Serve You Rx is a full-service pharmacy benefit manager (PBM) with unquestionable flexibility and an unwavering commitment to doing what’s best for its clients. With a fervent focus on those it serves, including insurance brokers, consultants, third-party administrators, and their clients, Serve You Rx delivers exceptional service and tailored, cost-effective benefit solutions. Independent and privately held for over 36 years, Serve You Rx can implement new groups in 30 days or less and say “yes” to a wide variety of viable solutions. Known for its adaptability, quality, and client-centricity, Serve You Rx aims to be a benchmark for better client service.
